Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Näyhä, V.
Right arrow Articles by Stenbäck, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Näyhä, V.
Right arrow Articles by Stenbäck, F.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Skin Cancer
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Stage-Dependent Expression of an Angiogenic Agent and Vascular Organization in Experimental Skin Tumor Development

Veera Näyhä

Department of Pathology, University of Oulu, Oulu, Finland

Jaakko Laitakari

Department of Pathology, University of Oulu, Oulu, Finland, Department of Oto-Rhino-Laryngology, University of Oulu, Oulu, Finland

Frej Stenbäck

Department of Pathology, University of Oulu, Oulu, Finland

Increased angiogenesis and expression of antibodies to vascular endothelial growth factor (VEGF), an angiogenic agent, have been shown in the tumor development of many tissues. Areas of skin expressing VEGF and total volume of vessels expressing laminin in the wall were measured in chemical carcinogen-exposed mice using CAS-200 morphometry apparatus having a sensitivity exceeding 99% and reproducibility exceeding 99%. The area of VEGF expression was increased in carcinogen-exposed skin, dysplasia and in well-differentiated squamous cell carcinomas, but decreased in squamous cell carcinomas with decreased degree of differentiation. The vessel volume increased prior to the formation of tumors in carcinogen-exposed skin as well as in highly malignant neoplasms. In well-differentiated squamous cell carcinomas with an expansive growth pattern, the vessels were parallel to the basal membrane, in moderately differentiated tumors the vessels were in the direction of tumor invasion, and in poorly differentiated tumors, active angiogenesis consisted of numerous, enlarged vessels within the tumor. This study showed increased VEGF expression and number of vessels occurring in early stages of skin tumor development, pointing to a role of angiogenesis in chemical risk assessment and in cancer prevention. Altered vessel structure and vessel arrangement were distinct in later stages of tumor growth and in malignant neoplasms, pointing to the utility of detailed vessel analysis in neoplasm characterization.

Key Words: Angiogenesis • vascular endothelial growth factor (VEGF) • mouse skin tumors • blood vessels.

References

  • Albo D., Granick MS, Jhala N., Atkinson B., Solomon MP (1994). The relationship of angiogenesis to biological activity in human squamous cell carcinomas of the head and neck. Ann Plast Surg 32: 588—594.[Web of Science][Medline] [Order article via Infotrieve]
  • Arbeit JM, Olson DC, Hanahan D. (1996). Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice. Oncogene 13: 1847—1857.[Web of Science][Medline] [Order article via Infotrieve]
  • Bergers G., Hanahan D., Coussens LM (1998). Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int J Dev Biol 42: 995—1002.[Web of Science][Medline] [Order article via Infotrieve]
  • Bergers G., Javaherian K., Lo KM, Folkman J., Hanahan D. (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808—812.[Abstract/Free Full Text]
  • Bleuel K., Popp S., Fusenig NE, Stanbridge EJ, Boukamp P. (1999). Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc Natl Acad Sci USA 96: 2065—2070.[Abstract/Free Full Text]
  • Bolontrade MF, Stern MC, Binder RL, Zenklusen JC, Gimenez-Conti IB, Conti CJ (1998). Angiogenesis is an early event in the development of chemically induced skin tumors. Carcinogenesis 19: 2107—2113.[Abstract/Free Full Text]
  • Burian M., Quint C., Neuchrist C. (1999). Angiogenic factors in laryngeal carcinomas: Do they have prognostic relevance? Acta Otolaryngol 119: 289—292.[CrossRef][Medline] [Order article via Infotrieve]
  • Brown LF, Detmar M., Claffey K., Nagy JA, Feng D., Dvorak AM, Dvorak HF (1997). Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine. EXS 79: 233—269.[Medline] [Order article via Infotrieve]
  • Brustmann H., Riss P., Naude S. (1997). The relevance of angiogenesis in benign and malignant epithelial tumors of the ovary: A quantitative histologic study. Gynecol Oncol 67: 20—26.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Carmeliet P., Collen D. (2000). Transgenic mouse models in angiogenesis and cardiovascular disease. J Pathol 190: 387—405.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cohen T., Gitay-Goren H., Sharon R., Shibuya M., Halaban R., Levi BZ, Neufeld G. (1995). VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 270: 11322—11326.[Abstract/Free Full Text]
  • Conn G., Bayne ML, Soderman DD, Kwok PW, Sullivan KA, Palisi TM, Hope, DA, Thomas KA (1990). Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci USA 87: 2628—2632.[Abstract/Free Full Text]
  • Conn G., Soderman DD, Schaeffer MT, Wile M., Hatcher VB, Thomas KA (1990). Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line. Proc Natl Acad Sci USA 87: 1323— 1327.[Abstract/Free Full Text]
  • Connolly DT, Heuvelman DM, Nelson R., Olander JV, Eppley BL, Delfino, JJ, Siegel NR, Leimgruber RM, Feder J. (1989). Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84: 1470—1478.[Web of Science][Medline] [Order article via Infotrieve]
  • Conti CJ (2002). Vascular endothelial growth factor: Regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy. Oncologist 7(Suppl 3): 4—11.[Free Full Text]
  • Detmar M. (2000). The role of VEGF and thrombospondins in skin angiogenesis. J Dermatol Sci Suppl 1: S78—S84.
  • Detmar M., Brown LF, Schon MP, Elicker BM, Velasco P., Richard L., Fukumura D., Monsky W., Claffey KP, Jain RK ( 1998). Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 111: 1—6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Detmar M. (1996). Molecular regulation of angiogenesis in the skin. J Invest Dermatol 106: 207—208.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Detmar M. (2000). Tumor angiogenesis. J Investig Dermatol Symp Proc 5: 20—23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Enholm B., Karpanen T., Jeltsch M., Kubo H., Stenback F., Prevo R., Jackson DG, Ylä-Herttuala S., Alitalo K. (2001). Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res 88: 623—636.[Abstract/Free Full Text]
  • Ferrara N., Alitalo K. (1999). Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5: 1359—1364.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Folberg R., Hendrix MJ, Maniotis AJ (2000). Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 156: 361—381.[Abstract/Free Full Text]
  • Folkman J. (1997). Angiogenesis and angiogenesis inhibition: An overview. EXS 79: 1—8.[Medline] [Order article via Infotrieve]
  • Folkman J. (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4—6.[Free Full Text]
  • Folkman J. (1996). New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 32A: 2534—2539.[CrossRef]
  • Folkman J., Watson K., Ingber D., Hanahan D. (1989). Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58—61.[CrossRef][Medline] [Order article via Infotrieve]
  • Gasparini G., Weidner N., Bevilacqua P., Maluta S., Dalla PP, Caffo O., Barbareschi M., Boracchi P., Marubini E., Pozza F. (1994). Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12: 454—466.[Abstract]
  • Gasparini G. (2001). Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol 37: 97— 114.[Web of Science][Medline] [Order article via Infotrieve]
  • Goodall CM, Sanders AG, Shubik P. (1965). Studies of vascular patterns in living tumors with a transparent chamber inserted in hamster cheek pouch. J Natl Cancer Inst 35: 497—521.[Medline] [Order article via Infotrieve]
  • Gorstein F. (1988). The dynamic extracellular matrix. Hum Pathol 19: 751— 752.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Guidi AJ, Abu-Jawdeh G., Berse B., Jackman RW, Tognazzi K., Dvorak HF, Brown LF (1995). Vascularpermeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 87: 1237—1245.[Abstract/Free Full Text]
  • Hanahan D., Folkman J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353—364.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hanahan D., Christofori G., Naik P., Arbeit J. (1996). Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 32A: 2386— 2393.[CrossRef]
  • Kandel J., Bossy-Wetzel E., Radvanyi F., Klagsbrun M., Folkman J., Hanahan D. (1991). Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66: 1095—1104.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kuwano H., Sonoda K., Yasuda M., Sumiyoshi K., Nozoe T., Sugimachi K. (1997). Tumor invasion and angiogenesis in early esophageal squamous cell carcinoma. J Surg Oncol 65: 188—193.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Laitakari J., Stenback F. (2001). Morphometrical characteristics of cell proliferation and p53 expression in development of experimentally induced respiratory tumors. Analyt Quant Cytol Histol 23: 273—286.
  • Larcher F., Robles AI, Duran H., Murillas R., Quintanilla M., Cano A., Conti CJ, Jorcano JL (1996). Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 56: 5391—5396.[Abstract/Free Full Text]
  • Leedy DA, Trune DR, Kronz JD, Weidner N., Cohen JI (1994). Tumor angiogenesis, the p53 antigen, and cervical metastasis in squamous carcinoma of the tongue. Otolaryngol Head Neck Surg 111: 417—422.[Web of Science][Medline] [Order article via Infotrieve]
  • Leung DW, Cachianes G., Kuang WJ, Goeddel DV, Ferrara N. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306—1309.[Abstract/Free Full Text]
  • Levy AP, TamargoR., Brem H., Nathans D. (1989). An endothelial cell growth factor from the mouse neuroblastoma cell line NB41. Growth Factors 2: 9— 19.[Medline] [Order article via Infotrieve]
  • Li CY, Shan S., Huang Q., Braun RD, Lanzen J., Hu K., Lin P., Dewhirst MW (2000). Initial stages of tumor cell-induced angiogenesis: Evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92: 143—147.[Abstract/Free Full Text]
  • Liotta LA, Abe S., Robey PG, Martin GR (1979). Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor. Proc Natl Acad Sci USA 76: 2268—2272.[Abstract/Free Full Text]
  • Macchiarini P., Fontanini G., Hardin MJ, Squartini F., Angeletti CA (1992). Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 340: 145—146.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Macchiarini P., Fontanini G., Hardin JM, Pingitore R., Angeletti CA (1992). Most peripheral, node-negative, non-small-cell lung cancers have low proliferative rates and no intratumoral and peritumoral blood and lymphatic vessel invasion. Rationale for treatment with wedge resection alone. J Thorac Cardiovasc Surg 104: 892—899.[Abstract]
  • Mäkinen M., Stenbäck F. (1998). Skin tumor development and keratin expression in different experimental models. Relation to inducing agent and target tissue structure. Exp Toxicol Pathol 50: 199—208.[Web of Science][Medline] [Order article via Infotrieve]
  • Mäkinen M., Jussila T., Stenbäck F. (1998). Epidermal cell adhesion and basement membrane alterations in experimental skin tumour development. Anticancer Res 18: 877—884.[Web of Science][Medline] [Order article via Infotrieve]
  • Meiron M., Anunu R., Scheinman EJ, Hashmueli S., Levi BZ ( 2001). New isoforms of VEGF are translated from alternative initiation CUG codons located in its 5'UTR. Biochem Biophys Res Commun 282: 1053— 1060.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mineta H., Miura K., Ogino T., Takebayashi S., Misawa K., Ueda Y., Suzuki I., Dictor M., Borg A., Wennerberg J. (2000). Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br J Cancer 83: 775—781.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Moriyama M., Kumagai S., Kawashiri S., Kojima K., Kakihara K., Yamamoto E. (1997). Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 33: 369—374.[Web of Science][Medline] [Order article via Infotrieve]
  • Neuchrist C., Quint C., Pammer A., Burian M. (1999). Vascular endothelial growth factor (VEGF) and microvessel density in squamous cell carcinomas of the larynx: An immunohistochemical study. Acta Otolaryngol 119: 732— 738.[CrossRef][Medline] [Order article via Infotrieve]
  • Plate KH, BreierG., Weich HA, Risau W. (1992). Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845—848.[CrossRef][Medline] [Order article via Infotrieve]
  • Plouet J., Schilling J., Gospodarowicz D.( 1989). Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 8: 3801—3806.[Web of Science][Medline] [Order article via Infotrieve]
  • Pozzi A., Moberg PE, Miles LA, Wagner S., Soloway P., Gardner HA (2000). Elevated matrix metalloprotease and angiostatin levels in integrin {alpha}1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci USA 97: 2202—2207.[Abstract/Free Full Text]
  • Risau W. (1990). Angiogenic growth factors. Progr Growth Factor Res 2(1): 71—79.[CrossRef]
  • Sauter ER, Nesbit M., Watson JC, Klein-Szanto A., Litwin S., Herlyn M. (1999). Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 5: 775—782.[Abstract/Free Full Text]
  • Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983—985.[Abstract/Free Full Text]
  • Skobe M., Rockwell P., Goldstein N., Vosseler S., Fusenig NE (1997). Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3: 1222— 1227.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Smith-McCune K., Zhu YH, Hanahan D., Arbeit J. (1997). Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res 57: 1294—1300.[Abstract/Free Full Text]
  • Smith-McCune KK, Weidner N. (1994). Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 54: 800— 804.[Abstract/Free Full Text]
  • Stenbäck F., Mäkinen M., Jussila T. (1998). p53 expression in skin carcinogenesis: Relation to cell proliferation and tumour growth. Eur J Cancer 34: 1415—1424.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stenbäck F. (1978). Life history and histopathology of ultraviolet light-induced skin tumors. Natl Cancer Inst Monogr 50: 57—70.
  • Stenbäck F., Mäkinen M., Jussila T., Kauppila S., Risteli J., Talve L., Risteli L. (1999). The extracellular matrix in skin tumor development—A morphological study. J Cutan Path 26: 327—338.[CrossRef][Medline] [Order article via Infotrieve]
  • Strieth S., Hartschuh W., Pilz L., Fusenig NE (2000). Angiogenic switch occurs late in squamous cell carcinomas of human skin. Br J Cancer 82: 591—600.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tae K., El-Naggar AK, Yoo E., Feng L., Lee JJ, Hong WK, Hittelman WN, Shin DM ( 2000). Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clin Cancer Res 6: 2821— 2828.[Abstract/Free Full Text]
  • Ushmorov AG, Furstenberger G., Faissner A., Marks F. (1994). Effects of complete and incomplete tumor promoters on hair growth, angiogenesis, and tenascin expression in the skin of NMRI mice. Carcinogenesis 15: 2739—2745.[Abstract/Free Full Text]
  • Valtola R., Salven P., Heikkila P., Taipale J., Joensuu H., Rehn M., Pihlajaniemi T., Weich H., deWaal R., Alitalo K. (1999). VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154: 1381— 1390.[Abstract/Free Full Text]
  • Warren BA (1966). The ultrastructure of capillary sprouts induced by melanoma transplants in the golden hamster. J Royal Microscop Soc 86: 177—187.
  • Warren BA, Shubik P. (1966). The growth of the blood supply to melanoma transplants in the hamster cheek pouch. Lab Invest 15: 464— 478.[Web of Science][Medline] [Order article via Infotrieve]
  • Weidner N. (1993). Tumor angiogenesis: Review of current applications in tumor prognostication. Semin Diagn Pathol 10: 302—313.[Web of Science][Medline] [Order article via Infotrieve]
  • Weidner N. (2000). Angiogenesis as a predictor of clinical outcome in cancer patients. Hum Pathol 31: 403—405.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Weidner N., Carroll PR, Flax J., Blumenfeld W., Folkman J. (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401—409.[Abstract]
  • Weidner N., Folkman J. (1996). Tumor vascularity as a prognostic factor in breast cancer. Import Adv Oncol 167—190.
  • Weidner N., Semple JP, Welch WR, Folkman J. (1991). Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 324: 1—8.[Abstract]
  • Weninger W., Uthman A., Pammer J., Pichler A., Ballaun C., Lang IM, Plettenberg A., Bankl HC, Sturzl M., Tschachler E. (1996). Vascular endothelial growth factor production in normal epidermis and in benign and malignant epithelial skin tumors. Lab Invest 75: 647—657.[Web of Science][Medline] [Order article via Infotrieve]
  • Zhang HT, Scott PA, Morbidelli L., Peak S., Moore J., Turley H., Harris AL, Ziche M., Bicknell R. (2000). The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 83: 63—68.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Toxicologic Pathology, Vol. 31, No. 5, 539-548 (2003)
DOI: 10.1080/01926230390226654
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Näyhä, V.
Right arrow Articles by Stenbäck, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Näyhä, V.
Right arrow Articles by Stenbäck, F.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Skin Cancer
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?